无创正压通气应用于慢性阻塞性肺疾病并呼吸衰竭的临床治疗价值分析

Value of Noninvasive Positive Pressure Ventilation in the Treatment of Chronic Obstructive Pulmonary Disease with Respiratory Failure

目的:探讨无创正压通气应治疗慢性阻塞性肺疾病并呼吸衰竭(COPD)临床疗效及对患者血清炎症因子的影响。方法:选取2018年1月~2020年1月本院收治的84例COPD合并呼吸衰竭患者为研究对象,分为观察组和对照组各42例,患者均接受常规对症治疗,包括抗感染、祛痰、止咳、控制气道炎症、纠正酸碱失衡、恢复电解质平衡、扩张气道等。在此基础上,观察组患者采取无创正压通气治疗。治疗后评价两组患者的临床疗效及对血清炎症因子的影响。结果:观察组患者的总有效率为88.10%,对照组为69.05%,差异明显(P<0.05);观察组患者的病死率为2.38%,再入院率为9.52%,对照组分别为16.67%、28.57%,差异明显(P<0.05);治疗后,观察组患者的IL-6、TNF-α水平明显低于对照组(P<0.05)。结论:对COPD合并呼吸衰竭患者应用无创正压通气治疗可提高临床疗效,降低病死率及再住院率,改善炎症因子水平。

Objective:To explore the clinical efficacy of non-invasive positive pressure ventilation in the treatment of chronic obstructive pulmonary disease and respiratory failure(COPD)and its influence on patients'serum inflammatory factors.Methods:A total of 84 patients with COPD and respiratory failure admitted to our hospital from January 2018 to January 2020 were selected as the research subjects.They were divided into observation group and control group,each with 42 cases.The patients received conventional symptomatic treatment,including anti-infection and anti-infection treatment.Phlegm,cough relieving,controlling airway inflammation,correcting acid-base imbalance,restoring electrolyte balance,expanding airway,etc.On this basis,patients in the observation group were treated with non-invasive positive pressure ventilation.After treatment,the clinical efficacy of the two groups of patients and the effect on serum inflammatory factors were evaluated.Results:The total effective rate of the observation group was 88.10%and that of the control group was 69.05%.The difference was significant(P<0.05);the fatality rate of the observation group was 2.38%,the readmission rate was 9.52%,and the control group was 16.67%,28.57%,the difference was significant(P<0.05);after treatment,the levels of IL-6 and TNF-αin the observation group were significantly lower than those in the control group(P<0.05).Conclusion:The application of non-invasive positive pressure ventilation to patients with COPD and respiratory failure can improve the clinical efficacy,reduce the mortality rate and rehospitalization rate,and improve the level of inflammatory factors.